SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-125038"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-125038" > Reduction in fractu...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003377naa a2200397 4500
001oai:DiVA.org:uu-125038
003SwePub
008100507s2009 | |||||||||||000 ||eng|
024a urn:nbn:se:uu:diva-1250382 urn
024a https://doi.org/10.1007/s00223-009-9299-62 DOI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
100a Langdahl, Bente L.4 aut
2451 0a Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide :b 18-month data from the European Forsteo Observational Study (EFOS)
264 1c 2009
338 a print2 rdacarrier
520 a The European Forsteo Observational Study was designed to examine the effectiveness of teriparatide in postmenopausal women with osteoporosis treated for up to 18 months in normal clinical practice in eight European countries. The incidence of clinical vertebral and nonvertebral fragility fractures, back pain, and health-related quality of life (HRQoL, EQ-5D) were assessed. Spontaneous reports of adverse events were collected. All 1,648 enrolled women were teriparatide treatment-naive, 91.0% of them had previously received other anti-osteoporosis drugs, and 72.8% completed the 18-month study. A total of 168 incident clinical fractures were sustained by 138 (8.8%) women (821 fractures/10,000 patient-years). A 47% decrease in the odds of fracture in the last 6-month period compared to the first 6-month period was observed (P < 0.005). Mean back pain VAS was reduced by 25.8 mm at end point (P < 0.001). Mean change from baseline in EQ-VAS was 13 mm by 18 months. The largest improvements were reported in the EQ-5D subdomains of usual activities and pain/discomfort. There were 365 adverse events spontaneously reported, of which 48.0% were considered related to teriparatide; adverse events were the reason for discontinuation for 79 (5.8%) patients. In conclusion, postmenopausal women with severe osteoporosis who were prescribed teriparatide in standard clinical practice had a significant reduction in the incidence of fragility fractures and a reduction in back pain over an 18-month treatment period. This was associated with a clinically significant improvement in HRQoL. Safety was consistent with current prescribing information. These results should be interpreted in the context of the open-label, noncontrolled design of the study.
653 a MEDICINE
653 a MEDICIN
700a Rajzbaum, Gerald4 aut
700a Jakob, Franz4 aut
700a Karras, Dimitrios4 aut
700a Ljunggren, Östenu Uppsala universitet,Institutionen för medicinska vetenskaper,Metabolic Bone Disease4 aut0 (Swepub:uu)osteljun
700a Lems, Willem F.4 aut
700a Fahrleitner-Pammer, Astrid4 aut
700a Walsh, J. Bernard4 aut
700a Barker, Clare4 aut
700a Kutahov, Alexey4 aut
700a Marin, Fernando4 aut
710a Uppsala universitetb Institutionen för medicinska vetenskaper4 org
773t Calcified Tissue Internationalg 85:6, s. 484-493q 85:6<484-493x 0171-967Xx 1432-0827
8564 8u http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-125038x lärosäteslänky Till lärosätets (uu) databas
8564 8u https://doi.org/10.1007/s00223-009-9299-6

Hitta via bibliotek

Till lärosätets databas

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy